TY - JOUR
T1 - A pure likelihood approach to the analysis of genetic association data
T2 - An alternative to Bayesian and frequentist analysis
AU - Strug, Lisa J.
AU - Hodge, Susan E.
AU - Chiang, Theodore
AU - Pal, Deb K.
AU - Corey, Paul N.
AU - Rohde, Charles
N1 - Funding Information:
We thank the patients and their families who contributed data to the Rolandic Epilepsy study, as well as the referring physicians. This research was funded by the NIH, grants HG-004314 (LJS), MH-48858, DK-31813 (SEH), and NS047530 (DKP). We acknowledge the kind support of The Hospital for Sick Children’s New Ideas Grant Program (LJS), the Natural Sciences and Engineering Research Council of Canada (LJS), the Ontario Ministry of Research and Innovation Early Researcher Awards Program (LJS), members of the Partnership for Pediatric Epilepsy Research, which includes the American Epilepsy Society, the Epilepsy Foundation, Anna and Jim Fantaci, Fight Against Childhood Epilepsy and Seizures (faces), Neurotherapy Ventures Charitable Research Fund, and Parents Against Childhood Epilepsy (PACE) (DKP). We thank the Epilepsy Foundation through the generous support of the Charles L Shor Foundation for Epilepsy Research Inc. and People Against Childhood Epilepsy (PACE) (DKP).
PY - 2010/8
Y1 - 2010/8
N2 - Investigators performing genetic association studies grapple with how to measure strength of association evidence, choose sample size, and adjust for multiple testing. We apply the evidential paradigm (EP) to genetic association studies, highlighting its strengths. The EP uses likelihood ratios (LRs), as opposed to P-values or Bayes factors, to measure strength of association evidence. We derive EP methodology to estimate sample size, adjust for multiple testing, and provide informative graphics for drawing inferences, as illustrated with a Rolandic Epilepsy (RE) fine-mapping study. We focus on controlling the probability of observing weak evidence for or against association (W) rather than type I errors (M). For example, for LR≥32 representing strong evidence, at one locus with n=200 cases, n=200 controls, W=0.134, whereas M=0.005. For n=300 cases and controls, W=0.039 and M=0.004. These calculations are based on detecting an OR1.5. Despite the common misconception, one is not tied to this planning value for analysis; rather one calculates the likelihood at all possible values to assess evidence for association. We provide methodology to adjust for multiple tests across m loci, which adjusts M and W for m. We do so for (a) single-stage designs, (b) two-stage designs, and (c) simultaneously controlling family-wise error rate (FWER) and W. Method (c) chooses larger sample sizes than (a) or (b), whereas (b) has smaller bounds on the FWER than (a). The EP, using our innovative graphical display, identifies important SNPs in elongator protein complex 4 (ELP4) associated with RE that may not have been identified using standard approaches.
AB - Investigators performing genetic association studies grapple with how to measure strength of association evidence, choose sample size, and adjust for multiple testing. We apply the evidential paradigm (EP) to genetic association studies, highlighting its strengths. The EP uses likelihood ratios (LRs), as opposed to P-values or Bayes factors, to measure strength of association evidence. We derive EP methodology to estimate sample size, adjust for multiple testing, and provide informative graphics for drawing inferences, as illustrated with a Rolandic Epilepsy (RE) fine-mapping study. We focus on controlling the probability of observing weak evidence for or against association (W) rather than type I errors (M). For example, for LR≥32 representing strong evidence, at one locus with n=200 cases, n=200 controls, W=0.134, whereas M=0.005. For n=300 cases and controls, W=0.039 and M=0.004. These calculations are based on detecting an OR1.5. Despite the common misconception, one is not tied to this planning value for analysis; rather one calculates the likelihood at all possible values to assess evidence for association. We provide methodology to adjust for multiple tests across m loci, which adjusts M and W for m. We do so for (a) single-stage designs, (b) two-stage designs, and (c) simultaneously controlling family-wise error rate (FWER) and W. Method (c) chooses larger sample sizes than (a) or (b), whereas (b) has smaller bounds on the FWER than (a). The EP, using our innovative graphical display, identifies important SNPs in elongator protein complex 4 (ELP4) associated with RE that may not have been identified using standard approaches.
KW - evidential paradigm
KW - multiple testing
KW - profile likelihood
UR - http://www.scopus.com/inward/record.url?scp=77954954900&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77954954900&partnerID=8YFLogxK
U2 - 10.1038/ejhg.2010.47
DO - 10.1038/ejhg.2010.47
M3 - Article
C2 - 20424645
AN - SCOPUS:77954954900
SN - 1018-4813
VL - 18
SP - 933
EP - 941
JO - European Journal of Human Genetics
JF - European Journal of Human Genetics
IS - 8
ER -